mProX™ Human LILRB1 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

LILRB1, or leukocyte immunoglobulin-like receptor subfamily B member 1, has various applications in different fields. In the context of cancer immunotherapy, LILRB1 has gained attention as a potential target for immune checkpoint therapy. It is expressed by immune cells such as macrophages, cytotoxic lymphocytes, T cells, and natural killer cells, and its interaction with human leukocyte antigen (HLA) class I molecules regulates immune responses. LILRB1 acts as a phagocytosis checkpoint on macrophages by recognizing HLA class I, inhibiting the phagocytic uptake of cancer cells. Blocking the HLA class I:LILRB1 axis may enhance phagocytosis by macrophages and promote cytotoxic functions of T cells and natural killer cells. LILRB1-specific antibodies are currently being developed for pre-clinical and clinical use in cancer immunotherapy. In the context of sickle cell disease, genetic polymorphisms of HLA-F and LILRB1 have been associated with alloimmunization susceptibility in patients receiving red blood cell transfusions. These polymorphisms affect the expression levels of HLA-F and LILRB1 proteins, which are involved in immune tolerance mechanisms. Understanding these genetic factors can help optimize blood product compatibility and improve patient outcomes. Additionally, LILRB1 has been studied in the context of ulcerative colitis, a chronic inflammatory bowel disease. Gene expression analysis has identified LILRB1 as one of the key genes associated with the severity of ulcerative colitis. It is involved in inflammation, migration, and invasion of synovial tissue-derived fibroblasts through the activation of the ERK/JNK signaling pathway. Finally, LILRB1 has been investigated as a potential therapeutic target in joint inflammation of rheumatoid arthritis. Soluble LILRA3, a receptor related to LILRB1, is increased in the synovial fluid and serum of rheumatoid arthritis patients and promotes the activation, migration, and invasion of fibroblast-like synoviocytes. These findings suggest that targeting LILRB1/LILRA3 may have therapeutic implications in various diseases, including cancer, sickle cell disease, ulcerative colitis, and rheumatoid arthritis.